E-LIB Suche - Ergebnisse für: Rogers, Kerry

1

Impact of ibrutinib dose adjustment on TTNT in first-line C..:

Ghosh, Nilanjan ; Wang, Ruibin ; Qureshi, Zaina P....
Blood Neoplasia. 1 (2024) 3 - p. 100022 , 2024

Link: https://doi.org/10.1016/..

2

A multicenter study of venetoclax-based treatment for patie..:

Hampel, Paul J. ; Swaminathan, Mahesh ; Rogers, Kerry A....
Blood Advances. 8 (2024) 10 - p. 2342-2350 , 2024

Link: https://doi.org/10.1182/..

3

GAIA/CLL13 provides further insight on venetoclax use in ch..:

Rogers, Kerry A
The Lancet Oncology. 25 (2024) 6 - p. 685-687 , 2024

Link: https://doi.org/10.1016/..

4

Comparison of karyotype scoring guidelines for evaluating k..:

Avenarius, Matthew R. ; Huang, Ying ; Kittai, Adam S....
Leukemia. 38 (2024) 3 - p. 676-678 , 2024

Link: https://doi.org/10.1038/..

5

Racial disparities in chronic lymphocytic leukemia/small ly..:

Kittai, Adam S. ; Hang, Ying ; Bhat, Seema A....
American Journal of Hematology. 99 (2024) 4 - p. 780-784 , 2024

Link: https://doi.org/10.1002/..

6

Single‐center study of outcomes of patients with hairy cell..:

Annunzio, Kaitlin ; Ozga, Michael ; Huang, Ying...
eJHaem. 4 (2023) 4 - p. 1200-1202 , 2023

Link: https://doi.org/10.1002/..

7

CLL-194 Ibrutinib for Treatment of Relapsed-Refractory Chro..:

Burger, Jan ; Ghia, Paolo ; Munir, Talha...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S322-S323 , 2023

Link: https://doi.org/10.1016/..

8

Diminished humoral and cellular responses to SARS-CoV-2 vac..:

Ujjani, Chaitra ; Gooley, Ted A. ; Spurgeon, Stephen E....
Blood Advances. 7 (2023) 17 - p. 4728-4737 , 2023

Link: https://doi.org/10.1182/..

9

Evaluation of bleeding events in patients receiving acalabr..:

Kumar, Pooja S. ; Wiczer, Tracy ; Rosen, Lindsay...
Leukemia. 37 (2023) 7 - p. 1554-1557 , 2023

Link: https://doi.org/10.1038/..

10

Impact of sex on outcomes in patients with hairy cell leuke..:

Epperla, Narendranath ; Zhao, Qiuhong ; Anghelina, Mirela...
American Journal of Hematology. 98 (2023) 5 - p. , 2023

Link: https://doi.org/10.1002/..

11

CLL-586 Real-World Dosing Patterns and Outcomes Among Patie..:

Rogers, Kerry ; Lu, Xiaoxiao ; Emond, Bruno...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S330 , 2023

Link: https://doi.org/10.1016/..

12

Racial and socioeconomic disparities in CLL/SLL: analysis o..:

Kittai, Adam S. ; Huang, Ying ; Bhat, Seema A....
Blood Advances. 7 (2023) 11 - p. 2575-2579 , 2023

Link: https://doi.org/10.1182/..

13

P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONI..:

Ghia, Paolo ; Munir, Talha ; Burger, Jan...
HemaSphere. 7 (2023) S3 - p. e78258de , 2023

Link: https://doi.org/10.1097/..

14

Correction: Evaluation of bleeding events in patients recei..:

Kumar, Pooja S. ; Wiczer, Tracy ; Rosen, Lindsay...
Leukemia. 37 (2023) 7 - p. 1588-1588 , 2023

Link: https://doi.org/10.1038/..

15

POSTER: CLL-194 Ibrutinib for Treatment of Relapsed-Refract..:

Burger, Jan ; Ghia, Paolo ; Munir, Talha...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S173 , 2023

Link: https://doi.org/10.1016/..